Dechra Pharmaceuticals
Dechra Pharmaceuticals is one of the world's leading manufacturers of veterinary medicines and animal feed. The company is known for its innovative approach to drug development, sustainable growth and broad geographical presence. Since its inception, Dechra Pharmaceuticals has grown from a small British company into an international corporation whose products are trusted by veterinarians and pet owners around the world.
Country | Great Britain |
Year founded | 1997 |
CEO | Jesper Nordengaard |
Industry | Pharmaceuticals, veterinary medicines, dog food, cat food, medical supplies |
Number of employees | More than 2,100 as of the end of 2023 |
Share price (2025) | £37-£38 |
Market capitalisation as of 1 January 2024 | £4.39 billion (approximately $5.59 billion) |
Type of company | Public Limited Company (plc) |
Head office | Skipton, North Yorkshire, Great Britain |
Traded as | LSE: DPH |
History of Dechra Pharmaceuticals
Dechra Pharmaceuticals was founded in 1997 in Great Britain. Initially, the company was engaged in the distribution of veterinary drugs, and then moved on to its own scientific research and the production of innovative products for animals. Since its listing on the London Stock Exchange in 2000, Dechra Pharmaceuticals has been actively expanding its operations through acquisitions of other companies and the development of its own portfolio.
Dechra Pharmaceuticals
Key milestones in the company's development include:
- 2007 — Acquisition of VetXX, expanding the portfolio of veterinary products.
- 2010 — Launch of the Dechra Specific line of dog and cat food.
- 2013 — Introduction of hypoallergenic products to the market.
- 2019 — Acquisition of Osurnia, expanding the range of ear care products for animals.
- 2023 — acquisition by EQT, which was an important milestone in the holding company's development.
- 2024 — conclusion of a strategically important agreement with Invetx, which expanded the range of products for horses. The deal was worth $520 million, strengthening the company's position in the international market. Other important milestones in the company's development include the launch of new products for pets, including innovative solutions for maintaining pet health, and the expansion of production capacity in Europe and North America to meet growing demand.
- 2025 — continued active expansion into international markets, including entry into Asia and Latin America, launching new research centres to develop cutting-edge solutions in veterinary medicine, increasing investment in digital technologies and process automation to improve the company's efficiency, and strengthening partnerships with key distributors and veterinary clinics around the world.
Dechra Pharmaceuticals Jesper Nordengaard
Dechra Pharmaceuticals continues to demonstrate steady growth and development, remaining one of the leaders in the veterinary pharmaceutical market.
Dechra Pharmaceuticals Headquarters
Dechra Pharmaceuticals' head office is located in Skipton, North Yorkshire. It is a modern office complex with spacious laboratories and production facilities. Skipton was chosen for a reason — the town is located in the centre of an agricultural region, which ensures close ties with customers and suppliers.
Who owns Dechra Pharmaceuticals?
For many years, Dechra Pharmaceuticals operated as an independent public company (plc). Its main shareholders included institutional investors from the UK, Europe, and the USA. In 2023, a controlling stake was acquired by EQT, one of Europe's largest private investment companies. EQT now owns the majority stake, but the company remains public and continues to trade on the London Stock Exchange.
Dechra Pharmaceuticals: investor relations
EQT Dechra Pharmaceuticals
Dechra Pharmaceuticals attaches great importance to transparency and open dialogue with investors. The company regularly publishes annual and quarterly reports, holds meetings with shareholders and organises webinars on key business issues. Investor relations are based on the principles of honesty and long-term share value growth.
The Investor Relations section of the official website contains all the necessary documents: annual reports, investor presentations, corporate social responsibility reports, and IR department contact details.
What does Dechra Pharmaceuticals do?
Dechra Pharmaceuticals specialises in the development, manufacture and sale of veterinary medicines for domestic and farm animals. The company is known for its innovative solutions in the treatment of chronic diseases, allergies, infections and general animal health.
Dechra Pharmaceuticals' main goal is to improve the quality of life of animals through effective and safe medicines. The company's products are widely used in veterinary practice around the world. Particular attention is paid to the creation of hypoallergenic foods for dogs and cats, which allows you to care for pets with special needs.
Products
Dechra Pharmaceuticals dog and cat food
Dechra Pharmaceuticals' product range includes:
- Veterinary medicines for the treatment of various diseases
- Hypoallergenic dog food
- Hypoallergenic cat food
- Skin and ear care products for animals
- Medical devices for veterinary use
Key products:
Dechra Pharmaceuticals products
- Vetoryl — a drug for treating Cushing's disease in dogs.
- Cardisure — a drug for maintaining heart function.
- Malacetic — a skin and ear cleanser.
- Canaural Ear Drops — drops for treating ear infections.
- Dexacortone — an anti-inflammatory drug.
- Amoxibactin — a broad-spectrum antibiotic.
- TrizAural is a solution for ear washing.
- Xeno is an antiparasitic agent.
- Metrobactin is an antibacterial drug.
- Laxatract Syrup is a laxative.
- Pardale-V is a pain reliever for dogs.
- CleanAural is a product for ear hygiene.
- Intubeaze is a gel for facilitating intubation.
- Vetivex are solutions for infusions.
- Dechra Specific Allergen Management Plus is a specialised food for dogs with allergies.
- Tralieve Noah is a new generation analgesic.
Dechra Pharmaceuticals Annual Report and Results
In fiscal year 2024, the company showed steady growth in revenue and profitability. The main drivers of growth were the expansion of the product line, entry into new markets, and the successful integration of acquired assets.
Year | Revenue (£ million) | Operating profit (£ million) | Net profit (£ million) | Profit margin (%) |
|---|---|---|---|---|
2021 | 608 | 120 | 95 | 15.6 |
2022 | 681 | 135 | 105 | 15.4 |
2023 | 681 | 128 | 98 | 14.4 |
2024 | 725 | 145 | 112 | 15.8 |
2025 (forecast) | 760 | 155 | 120 | 16.0 |
The company has demonstrated steady revenue growth: compared to 2021, revenue increased by almost 12%. Profitability remains high thanks to effective cost management and continuous investment in research and development.
Dechra Pharmaceuticals shares
Dechra Pharmaceuticals share price dynamics
Dechra Pharmaceuticals shares are traded on the London Stock Exchange under the ticker symbol DPH. In recent years, the share price has shown positive dynamics thanks to business growth and strong financial results.
Year | Average share price (£) |
|---|---|
2019 | 28.5 |
2020 | 32.0 |
2021 | 36.4 |
2022 | 38.1 |
2023 | 37.5 |
2024 | 40.8 |
2025 | 42.3 (forecast) |
Between 2019 and 2025, the share price rose by more than 30%. The impact of the COVID-19 pandemic was minimal thanks to steady demand for veterinary medicines and feed. Following the announcement of EQT's acquisition in mid-2023, the share price rose further on expectations of further business expansion.
Dechra Pharmaceuticals
Dechra Pharmaceuticals dividends
Dechra Pharmaceuticals traditionally pays dividends to its shareholders. The amount of dividends depends on the company's financial results for the year.
In 2022, the dividend was approximately 45 pence per share.
In 2023, the dividend payment was maintained at the previous year's level.
As of 6 August 2024, the dividend yield of Dechra Pharmaceuticals (DPH.L) shares was 0.00%.
The dividend payment demonstrates the stability of the business and its commitment to the long-term interests of investors.
Additional information about Dechra Pharmaceuticals
Dechra Pharmaceuticals
Holdings and subsidiaries
Dechra Pharmaceuticals plc owns a number of subsidiaries in Europe, North America, and Asia. This allows for local production and rapid response to market demands.
Dechra Pharmaceuticals subsidiaries
Key subsidiaries:
- MedPharmex (Pomona, California).
- AST Farma B.V. (Oudewater, Netherlands).
- Le Vet Beheer B.V. (Oudewater, Netherlands).
- Apex Laboratories Pty Ltd. (Somersby, Australia).
- Putney, Inc. (Portland, Maine).
- Laboratorios Brovel S.A. de C.V. (Mexico City, Mexico).
- GENERA d.d. (Rakov Potok, Croatia).
- PSPC, Inc. (Melbourne, Florida).
Production
Production facilities are located in the UK (Skipton), Denmark, the Netherlands, the USA, and Australia. All factories are certified according to international GMP quality standards.
Dechra Pharmaceuticals actively recruits young specialists and experienced professionals. The official website lists vacancies in various fields: scientific research, production, sales, and marketing.
Dechra Quality Team
Conclusion
Dechra Pharmaceuticals is a striking example of a successful British company that has become one of the leaders in the global veterinary pharmaceutical industry over the past quarter century. The company's key advantages are innovation, a wide range of products (from hypoallergenic feed to complex medicines), stable financial policy, and investor confidence.
The company continues to grow rapidly under EQT's management, maintaining its focus on product quality and expanding its global presence. Steady revenue growth, stable share prices, and regular dividend payments make Dechra Pharmaceuticals attractive to both customers and investors.
